



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.

Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/18-19/041

Saturday November 17, 2018

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Sub: Newspaper Advertisement

Pursuant to Regulation 47 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith copies of newspaper advertisements.

Please take the same on your records.

Thanking You,

Yours Sincerely,

For Lasa Supergenerics Limited



Nidhi Kulshreshtha
Company Secretary and
Compliance Officer

Encl: as above.

POOJA ENTERTAINMENT AND FILMS LIMITED
 CIN: L9999MH1966PLC040559
 Reg. Office: Pooja House, 1st Floor, CTS No. 892-893, Opp. J. W. Marriott Hotel, Juhu Tara Road, Juhu, Mumbai-400 049 Tel: 022-26121613/14 | Fax: 022-26631275.
 Website: www.poojaentertainmentandfilms.in | Email Id: investor@poojaentertainmentandfilms.in

NOTICE

Notice is hereby given that in terms of the provisions of Regulation 29(1)(a) and Regulation 47(1)(a) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, 13th November, 2018 at 03.00 P.M. at the Registered Office of the Company situated at Pooja House, 1st Floor, CTS No. 892-893, Opp. J. W. Marriott Hotel, Juhu Tara Road, Juhu, Mumbai-400 049 to consider, approve and take on record, inter-alia, the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th September, 2018.

The information contained in the notice is also available on the website of the Company (www.poojaentertainmentandfilms.in) and also on the stock exchange website (www.bseindia.com).

By order of the Board,
For Pooja Entertainment And Films Limited
 Sd/-
Poonam Pokiya
 Company Secretary

Place: Mumbai
 Date: 06.11.2018

SHILPA MEDICARE LIMITED
 Reg. Off.: #12-6-214/A1, Hyderabad Road, Raichur, Kamataka-584135
 Ph: 08532-238704 Fax: 08532-238876 website: www.vbshilpa.com
 CIN:L85110KA1987PLC008739

NOTICE

Pursuant to Regulation 47 of SEBI read with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors will be held on Wednesday, the 14th day of November, 2018, inter alia to consider and publish the Un-audited Financial Results for the second quarter ended 30.09.2018 in compliance of Regulation 33 of the said regulations.

And the Trading Window for dealing in securities of the Company will be closed for all Directors, Designated Employees and Auditors (including their dependents) of the Company from 07th November, 2018 to 16th November, 2018 (both days inclusive).

For SHILPA MEDICARE LIMITED
 Sd/-
MADHUSUDHAN REDDY
 COMPANY SECRETARY & COMPLIANCE OFFICER

Date: 05-11-2018
 Place: Raichur

JCT LIMITED
 CIN: L17117PB1946PLC004565, Regd. Office: Village Chohal, Dist. Hoshiarpur (Punjab) -
 Phone: 46290000; Fax: -25812222, Website: www.jct.co.in, E-Mail: jctsecretarial@jctltd.com

NOTICE

NOTICE is hereby given that the meeting of the Board of Directors will be held on Wednesday, the 14th day of November, 2018, at New Delhi, to consider and approve the Un-audited Financial Results after Limited Review by the Statutory Auditors of the Company for the Half/Quarter ended 30th September, 2018.

The Notice is available on the website of the Company and BSE Limited.

For JCT Limited
 Sd/-
Sandeep Sachdeva
 Company Secretary

Place : New Delhi
 Date : 05.11.2018

नालको NALCO
 National Aluminium Company Limited
 (A Government of India Enterprise)

P/1, Nalco Bhawan, Nayapalli, Bhubaneswar - 751 013, Odisha, India
 CIN : L27203OR1981GO1000920
 A NAVRATNA COMPANY

NOTICE

In continuation to our notice dated 29.10.2018 and pursuant to Regulation 29 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that meeting of the Board of Directors of the Company scheduled to be held on Saturday, the 10th November, 2018 is postponed to be held on Monday, the 12th November, 2018, to consider inter-alia the Un-audited Financial Results for the quarter and six months ended 30th September, 2018.

Information in this regard is also available on the website of the Company i.e. www.nalcoindia.com and on the website of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com.

Place : Bhubaneswar
 Date : 05.11.2018

(N K Mohanty)
 Company Secretary

VICEROY HOTELS LIMITED
 CIN: L55101TG1965PLC001048
 Regd. Office: Plot No.20, Sector-1, 4th Floor, Huda Techno Enclave, Madhapur, Hyderabad - 500081, Telangana.
 Phone: 91 -40 2311 9695/4034 9999; Fax: 91 -40 - 4034 9828
 Email: secretarial@viceroypalace.in; Website: www.viceroypalace.in;

NOTICE

Notice is hereby given pursuant to Regulation 47(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that Meeting of the Board of Directors (RP) of Viceroypalace Hotels Limited, will be held on **Wednesday, 14 November, 2018**, at the registered office of the Company situated at Plot No.20, Sector-1, Survey No.64, 4th Floor, HUDA Techno Enclave, Hyderabad - 500081, Telangana, India, inter-alia to consider and approve the Un-Audited Financial Results (both Standalone & Consolidated) for the **Quarter and Half Year ended September 30, 2018**.

For VICEROY HOTELS LIMITED
 Sd/- (CMA K.K. Rao)
 Resolution Professional

Date : 05-11-2018
 Place : Hyderabad

NOTICE

Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Jenburkt Pharmaceutical Ltd. having address at Nirmal Apartment 93, Jayprakash Road, Andheri (W), Mumbai - 400058 have been Lost/misplaced and the holder(s) / purchaser(s) of the said Equity Shares have applied to the Company to issue duplicate Share Certificate(s).

Any person who has claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation.

Folio No.	Name of Share Holder:	No. of Shares:	Distinctive No.:	Certificate No.:
D000020	Devarshi Raskapur	200	1300101 - 1300300	701

Name: Devarshi Raskapur
 Dated: 06/11/2018

LASA SUPERGENERIC LIMITED
 Reg Off: C-105, MIDC, Mahad, Dist - Raigad, Mahad - 402309
 Corporate Office: B-207, CITIPOINT, Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai - 400059, Tel: +91 22 4970 1092
 Website: www.lasalabs.com, Email ID: investor@lasalabs.com
 CIN: L24233MH2016PLC274202

NOTICE

Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Notice is hereby given that the Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 14, 2018 at 1.00 p.m. at the Corporate Office of the Company. Inter-alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2018 and/or any other business/matter with the permission/approval of the Chairman.

The said notice is also available on the website of the Company at www.lasalabs.com and on the website of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com.

For Lasa Supergenerics Limited
 Sd/-
NidhiKulshreshtha
 Company Secretary

Place: Mumbai
 Date : November 5, 2018

MIRZA INTERNATIONAL LIMITED
 CIN : L19129UP1979PLC004821
 Regd. Off : 14/6, Civil Lines, Kanpur-208001 Phone : 0512-2530775
 E-mail : ankit.mishra@redtapeindia.com Website : www.mirza.co.in

NOTICE

Pursuant to Regulation 29 and 47 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 13, 2018 inter alia, to consider, approve and take on record the draft Unaudited Standalone And Consolidated Financial Statements of the Company for the Second Quarter & Half Year ended on September 30, 2018.

The said Notice may be accessed on the Company's website at www.mirza.co.in and also on the portals of respective Stock Exchange(s) i.e. www.nseindia.com and www.bseindia.com

By the order of Board
 For MIRZA INTERNATIONAL LIMITED
 (Ankit Mishra)
 Company Secretary & Compliance Officer

Place : Kanpur
 Date : November 05, 2018

pvp PVP VENTURES LIMITED
 (CIN: L72300TN1991PLC020122)
 Regd. Office: KRM Centre, 9th Floor, Door No. 2, Harrington Road, Chetpet, Chennai - 600 031, Tamil Nadu. Ph : 044 30285570
 Corp. Office: Plot No. 83 & 84, 4th Floor, Punnaiah Plaza, Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana. Phn: 040 67309999
 Email: investorrelations@pvpglobal.com; Website: www.pvpglobal.com

NOTICE

NOTICE is hereby given that pursuant to Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Meeting of Board of Directors of the Company will be held on Wednesday, November 14, 2018 at the Registered Office of the Company situated at Chennai, inter-alia, to consider and approve the Unaudited financial results

RISHI LASER LTD.
 CIN: L9999MH1992PLC066412
 612 V.K.Indl.Estate, 10/14 Pais Street, Byculia (W) Mumbai 400 011
 Email: rcl.mumbai@rishilaser.com Web: www.rishilaser.com

NOTICE

Notice is hereby given that pursuant to Regulation 47 read with Regulation 29 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company will be held on Wednesday, November 14, 2018, inter alia, to consider and approve the un-audited financial results for the quarter and six months ended September 30, 2018.

The said notice can be accessed on the Company's website at www.rishilaser.com



LASA SUPERGENERIC LIMITED

CORPORATE OFFICE : B/207, City Point, Near Kohimnor Hotel,
J B Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, India,
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com
FACTORY & REGD. OFFICE : Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra India.
Tel.: +91-2145-232101 / 232202 CIN : L24233MH2016PLC274202

Statement of Unaudited Financial Results for the Quarter ended 30th Sep, 2018

(Rs. In Lakhs)

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1. INCOME						
a. Revenue from Operations	4,074.48	3,292.06	6,453.07	7,366.54	12,554.09	24,583.88
b. Other Income	103.98	101.88	135.21	205.86	265.08	348.66
Total Income	4,178.45	3,393.94	6,588.28	7,572.40	12,819.17	24,932.54
2. Expenses						
a. Cost of Materials consumed	1,784.48	1,701.13	5,209.43	3,485.61	8,365.17	17,205.86
b. Cost of Traded Goods	1,174.13	599.79	-	1,773.91	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	41.35	(184.29)	(938.45)	(142.93)	(403.11)	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	-	-	231.29	231.29
e. Employee benefits expenses	285.93	268.21	256.82	554.14	494.29	1,027.09
f. Finance costs (Refer Note No.3)	397.72	360.96	242.19	758.68	495.57	1,134.35
g. Depreciation & amortizations expenses	485.07	480.13	609.11	965.21	850.63	1,816.66
h. Other Expenses	443.80	385.65	621.65	829.44	1,032.09	2,049.30
Total Expenses (a to g)	4,612.48	3,611.58	6,000.75	8,224.06	11,065.94	23,409.21
Exceptional Items	-	-	-	-	-	-
3. Profit / (Loss) before tax (1-2)	(434.03)	(217.64)	587.54	(651.67)	1,753.24	1,523.33
4. Tax expense						
Current Tax	-	-	119.58	-	361.90	316.33
Deferred Tax	(307.10)	79.97	(398.42)	(227.13)	(180.30)	(26.99)
Short / Excess income tax provision for earlier years	70.69	-	-	70.69	1.73	-
5. Net Profit / (Loss) after tax (3-4)	(197.61)	(297.61)	866.37	(495.22)	1,569.91	1,233.99
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	(0.38)	-	(0.36)	(0.38)	(1.11)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)	(197.99)	(297.61)	866.01	(495.60)	1,568.80	1,232.58
8. Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	8,952.04	9,150.03	9,783.86	8,952.04	9,783.86	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40
(b) Diluted	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40

See accompanying Notes to the Financial Results

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on 14th November, 2018 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the six month ended 30th September, 2018 are not comparable with previous comparative quarter ended 30th September, 2017.
- Finance cost includes Rs. 122.93 Lakhs being loss on account of foreign exchange fluctuations and Rs. 54.38 Lakhs being gain on account of foreign exchange fluctuations during the quarter ended 30th September, 2018 and 30th September, 2017 respectively.
- The Company has only one reportable segment i.e. Active Pharmaceutical Ingredients (API)
- The pricing pressure of most of the raw materials in reporting quarters continued to increase and rached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the major reasons for declined top lines in drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quarters.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors
For Lasa Supergenics Limited

Sd/-

Omkar Herlekar

Chairman & Managing Director

(DIN No. 01587154)

Place : Mumbai

Date : 14th November, 2018

[Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)]

Equity Share Capital
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)
Earnings Per Share (of Rs. 10/- each)
(for continuing and discontinued operations)
1. Basic:
2. Diluted:

Note:-

The aforesaid is an extract of the detailed format of quarter and half year ended 30th September, 2018 Regulation 33 of the SEBI (Listing Obligations and Disclosures) Regulations, 2015. The full format of the Unaudited Financial Results is available on the Company's website, www.bseindia.com, and on the Company's website.

Date : 13th November, 2018
Place : Mumbai

PUBLIC NOTICE

NOTICE is hereby given to the Public at large that MR. DILIP SHANTARAM PATIL & MR. PRAVIN SHANTARAM PATIL have applied for joint membership to the Society in the month of October 2018, in respect of erstwhile flat no. 2 on the Ground Floor, on the strength of Gift Deed dated 21st March 2018 executed by MRS. VIJAYALAXMI JANARDAN NARVEKAR in favour of said MR. DILIP SHANTARAM PATIL & MR. PRAVIN SHANTARAM PATIL. The said Gift Deed dated 21st March 2018 is duly stamped & registered under Registration No. BRL8-1335-2013 on 21/03/2018. Accordingly, the said MR. DILIP SHANTARAM PATIL & MR. PRAVIN SHANTARAM PATIL have submitted the relevant transfer documents to the Society.

However, the said VIJAYALAXMI JANARDAN NARVEKAR, as per the Death Certificate issued by the Department of Health, Municipal Corporation of Greater Mumbai, died on 18-10-2017.

Objections and claims, if any, are invited from the Public at large, within 15 days of publication of this Notice, with irrefutable documentary in respect of grant of joint membership of the erstwhile flat no. 2 on the Ground Floor in the names of the said MR. DILIP SHANTARAM PATIL & MR. PRAVIN SHANTARAM PATIL. If no claims and / or objections are received by the Society within 15 days of publication of this Notice, claim, if any, of any person in respect of said erstwhile flat no. 2 on the Ground Floor in the Society shall be deemed to have been waived and that the Society shall, accordingly, proceed with grant of joint membership to the said MR. DILIP SHANTARAM PATIL & MR. PRAVIN SHANTARAM PATIL in respect of erstwhile Flat No. 2 on the Ground Floor in the Society

Dated this 15th day of November 2018
Sd/-

Hon Secretary,
SHANTI CHS LTD.
12-A, Unnat Nagar Part II,
S.V. Road, Goregaon(W), Mumbai 40062

नमुने
अर्ज
सर्व
AND
HAR
सर्व
की,
विमान
सर्व
कलम
आहेत
१) व
स
२) उ
मा
अ)
ब) स
स
घ्यालय
त्यांची
तारखे
पत्त्याक
कॅफिया
कॅफिया
असे
निकाल
ही
महाराष्ट्र
१४/११
शिक



LASA SUPERGENERIC LIMITED

CORPORATE OFFICE : B/207, City Point, Near Kohimnor Hotel,
J B Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, India,
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com
FACTORY & REGD. OFFICE : Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra India.
Tel.: +91-2145-232101 / 232202 CIN : L24233MH2016PLC274202

Statement of Unaudited Financial Results for the Quarter ended 30th Sep, 2018
(Rs. in Lakhs)

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1. INCOME						
a. Revenue from Operations	4,074.48	3,292.06	6,453.07	7,366.54	12,554.09	24,583.88
b. Other Income	103.98	101.88	135.21	205.86	265.08	348.66
Total Income	4,178.45	3,393.94	6,588.28	7,572.40	12,819.17	24,932.54
2. Expenses						
a. Cost of Materials consumed	1,784.48	1,701.13	5,209.43	3,485.61	8,365.17	17,205.86
b. Cost of Traded Goods	1,174.13	599.79	-	1,773.91	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	41.35	(184.29)	(938.45)	(142.93)	(403.11)	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	-	-	231.29	231.29
e. Employee benefits expenses	285.93	268.21	256.82	554.14	494.29	1,027.09
f. Finance costs (Refer Note No.3)	397.72	360.96	242.19	758.68	495.57	1,134.35
g. Depreciation & amortizations expenses	485.07	480.13	609.11	965.21	850.63	1,816.66
h. Other Expenses	443.80	385.65	621.65	829.44	1,032.09	2,049.30
Total Expenses (a to g)	4,612.48	3,611.58	6,000.75	8,224.06	11,065.94	23,409.21
Exceptional Items	-	-	-	-	-	-
3. Profit / (Loss) before tax (1-2)	(434.03)	(217.64)	587.54	(651.67)	1,753.24	1,523.33
4. Tax expense						
Current Tax	-	-	119.58	-	361.90	316.33
Deferred Tax	(307.10)	79.97	(398.42)	(227.13)	(180.30)	(26.99)
Short / Excess income tax provision for earlier years	70.69	-	-	70.69	1.73	-
5. Net Profit / (Loss) after tax (3-4)	(197.61)	(297.61)	866.37	(495.22)	1,569.91	1,233.99
6. Other Comprehensive Income Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	(0.38)	-	(0.36)	(0.38)	(1.11)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)	(197.99)	(297.61)	866.01	(495.60)	1,568.80	1,232.58
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	8,952.04	9,150.03	9,783.86	8,952.04	9,783.86	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40
(b) Diluted	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40

See accompanying Notes to the Financial Results

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on 14th November, 2018 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenues are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the six month ended 30th September, 2018 are not comparable with previous comparative quarter ended 30th September, 2017.
- Finance cost includes Rs. 122.93 Lakhs being loss on account of foreign exchange fluctuations and Rs. 54.38 Lakhs being gain on account of foreign exchange fluctuations during the quarter ended 30th September, 2018 and 30th September, 2017 respectively.
- The Company has only one reportable segment i.e. Active Pharmaceutical Ingredients (API)
- The pricing pressure of most of the raw materials in reporting quarters continued to increase and rached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the major reasons for declined top lines in drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quarters.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors
For Lasa Supergenerics Limited

Sd/-
Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)

Place : Mumbai
Date : 14th November, 2018

401#
PARTIC
1 Total Income
2 Profit/(Loss)
4 Profit/(Loss) b
6 Net Profit/(Lo
7 Total Compri
8 Paid-up equi
9 Reserves and
Reserves as
previous acc
10 Earnings Per
items) (Face
(not annual
(a) Basic
(b) Diluted
Note:
1 The above
Regulatory
and BSE
2 The above
November
Date : 14.11.
Place : Mumbai
30 सप्टे
अ.
क्र.
Sub-tot
(2) Liabil
Non-c
(a) F
(b) F
(c) F
Sub-tot
Current
(a)
(b)
(c)
Sub-tot
Sub-tot
TOTAL
ED
Sd/-
ora
968

Andhra Pradesh State Co-operative Marketing Federation Ltd.,
#55-17-2 to 4, 5th Floor, Stalin Corporate Building, Near CGO Complex, Industrial Estate, Auto Nagar, Vijayawada-007

SHORT TENDER NOTICE FOR PROVIDING TRANSPORT, WAREHOUSING SERVICES AND SUPPLY OF SOUND USED 50 KG GUNNIES WITH MARKING AND 3 PLY NEW SUTHILI

Sealed tenders are invited from reputed and financially sound organizations for providing transportation, warehousing services and suppliers for supply of once used sound gunnies of 50 Kg (B-twill) to fill the 50 KG pulses/Maize with marking and 3ply new suthili (jute twine). The tender schedule can be obtained from this office on all working days during office hours from 08-11-2018 to 14-11-2018 up to 1:00 pm by paying Rs. 500/- towards tender schedule cost. The sealed tenders should reach this office on or before 1:30 pm on 14-11-2018. Tenders will be opened on the same day 2:30 pm the tender shall fulfill the conditions like EMD and other details laid down in the tender schedule

Sd/- MANAGING DIRECTOR

INDIAN OVERSEAS BANK
Thane Branch : Arjun Towers, 1st Floor, Gokhale Road, Naupada
Thane 400 602 Ph: 022-25376676,25408989. Email- iob0089@iob.in

PUBLIC NOTICE FOR E-AUCTION FOR SALE OF IMMOVABLE PROPERTY

Sale of immovable property mortgaged to Bank under Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (No.54 of 2002) whereas, the Authorized Officer of Indian Overseas Bank has taken possession of the following property pursuant to the notice issued under Section 13(2) of the Security Interest (Enforcement) Rules 2002 in the following loan account with right to sell the same on "AS IS WHERE IS BASIS" and "AS IS WHAT IS BASIS" for realization of Bank's dues plus interest & costs as detailed hereunder and whereas consequent upon failure to repay the dues, the undersigned in exercise of power conferred under Section 13(4) of the said Act proposes to realize the Bank's dues by sale of the said property. The sale will be done by the undersigned through e-auction platform provided at WebPortal (<http://www.iob.foreclosureindia.com>)

Name and address of the Borrowers	Name and address of the Guarantor
M/s Shiv Shakti Industries Prop. Mr Jitendrasinh Rupsinh Dodia, Plot No.65, Survey No.126, Khadoli, Silvassa 396 230 [UT of Dadra & Nagar Haveli]	1. Mr Jitendrasinh Rupsinh Dodia [Proprietor / Mortgagor] 2. Mrs Pritiben J Dodia [Mortgagor / Guarantor] No.1, Dodia's Residence, Mori Faliya, Naroli, Dadra & Nagar Haveli, Silvassa 396 230

Date of NPA: 30.09.2017 Date of Demand notice: 03.10.2017
Dues claimed in Demand Notice: Rs. 8,34,18,551.52 (as on 03.10.2017) with further interest & costs
Date of possession notice: 14.05.2018
Dues claimed in Possession Notice: Rs.9,07,61,979.54 as on 14.05.2018 with further interest & costs
*Outstanding dues of Local Self Government (Property Tax, Water sewerage, Electricity Bills etc) - Not available as per Bank record
*Bank's dues have priority over the Statutory dues

DESCRIPTION OF THE IMMOVABLE PROPERTY

Description of the Property	Reserve Price
1. All the present and future immovable assets of the hotel project including the land parcels situated at survey no. 226/3 admeasuring OH .87 m are situated at village Khanvel, UT of Dadra and Nagar Haveli standing in the name of Mr Jitendrasinh Dodia	Rs. 2229.00 lacs
2. The Non-agricultural land bearing survey No.7, admeasuring 1hector 82 are situated at village Kanadi,Besides Reliance Company, Silvassa of UT of Dadra and Nagar Haveli 396235 for industrial purpose standing in the name of Mr Jitendrasinh Dodia.	Rs. 912.00 lacs
3. Shop No.8,Admeasuring about 484 sq ft, Ground floor A/3 'B' Type, Anand Nagar, Survey No.71/1/5, Near District session Court, Silvassa-Kharval Road, Tokarkhada, Silvassa 396230 in the name of Mr Jitendrasinh Dodia.	Rs. 28,97,000.00
4. Flat No.5, admeasuring 1825 sq ft. on the first floor of the building L Pramukh Darshan II co-op. Housing society Limited at Survey No-341/2/2 of village Silvassa, Near Collector Bungalow, Silvassa-396230 in the name of Mr Jitendrasinh Dodia.	Rs. 44,84,000.00
5. Shop No.7, Admeasuring about 600 sq ft, Ground Floor, "B" Wing, Shiv Darshan Building, Survey No.1283 of village of Naroli, Near Primary Naroli School, Kumbhai Wadi, U.T.Dadra & Nagar Haveli owned by Mrs Pritiben J Dodia.	Rs. 27,36,000.00
6. Flat No.5, Admeasuring 1000 sq ft, GF, "B" Wing, Shiv Darshan Building, Survey No.1283 of village Naroli, Near Primary Naroli School, Kumbhai Wadi, U.T. Dadra & Nagar Haveli in the name of Mrs Pritiben J Dodia.	Rs. 22,85,000.00
7. Flat no.107, Admeasuring 1000 sq ft,1st Floor, "B" wing, Shiv Darshan Building, Survey No. 1283 of village Naroli, Near Primary Naroli School, Kumbhai Wadi, U.T. Dadra 7 Nagar Haveli in the name of Mrs Pritiben J Dodia.	Rs. 21,47,000.00

Date & Time of auction: 27.11.2018; 2.00 p.m. to 4.00 p.m.
EMD: 10% of Reserve Price for each property Bid increase amount: Rs 50,000/-
Auto extension time: 5 minutes. Inspection Date & Time: 10.11.2018 between 11.00 AM to 2.00 PM. Encumbrances if any: No known encumbrances
For terms and condition, please visit www.publishtenders.gov.in, www.iob.in & www.iob.foreclosureindia.com or call the undersigned at Ph No.022-25376676/25408989

Sd/-
Authorized Officer
Indian Overseas Bank

Date : 05.11.2018
Place : Mumbai

(This is a public announcement for information purposes only and not for publication or distribution and is not an Offer Document)
(Not for distribution outside India)

LASA
LASA SUPERGENERIC LTD

LASA SUPERGENERIC LIMITED

Our Company was incorporated as "Lasa Supergenerics Limited" on March 11, 2016 as a public company under the provisions of Companies Act, 2013 having registration number 274202 of 2016 with the Registrar of Companies, Mumbai ("RoC"). Our Company has received its Certificate of Incorporation dated March 11, 2016 from the Registrar of Companies, Mumbai.

Registered Office: C-105, MIDC, Mahad, Raigad - 402301, Maharashtra, India
Telephone: +91 21-4523-2101 / 202; Fax: NA
Contact Person: Nidhi Kulkshreshtha, Company Secretary and Compliance Officer;
E-mail: cs@lasalabs.com; **Website:** www.lasalabs.com
Corporate Identity Number: L24233MH2016PLC274202

PROMOTER OF THE COMPANY: OMKAR HERLEKAR

ISSUE OF [?] EQUITY SHARES WITH A FACE VALUE OF ₹ 10 EACH ("RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ [?] PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [?] PER RIGHTS EQUITY SHARE AGGREGATING UPTO ₹ 6,000 LACS TO OUR ELIGIBLE EQUITY SHAREHOLDERS ON A RIGHTS BASIS IN THE RATIO OF [?] FULLY PAID-UP RIGHTS EQUITY SHARE(S) FOR EVERY [?] FULLY PAID-UP EQUITY SHARE(S) HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. [?] ("THE ISSUE"). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARE IS [?] TIMES THE FACE VALUE OF THE EQUITY SHARE. FOR FURTHER DETAILS, PLEASE SEE THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE [?] OF THE DLOF.

This public announcement is being made in compliance with the provisions of Regulation 9(3) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended (the "SEBI ICDR Regulations"), to state that Lasa Supergenerics Limited is proposing, subject to requisite approvals, market conditions and other considerations, an issue of equity shares to equity shareholders on rights basis and has on November 6, 2018 filed the Draft Letter of Offer ("DLOF") with the Securities and Exchange Board of India (the "SEBI") at Mumbai, Maharashtra.

Pursuant to Regulation 9(1) of the SEBI ICDR Regulations, the DLOF filed with SEBI is open to public, for comments, if any. The DLOF is hosted on the website of SEBI at www.sebi.gov.in, website of recognized stock exchanges where the equity shares are listed i.e. BSE Limited at www.bseindia.com and the National Stock Exchange of India Limited at www.nseindia.com and website of the Lead Manager i.e. Saffron Capital Advisors Private Limited at www.saffronadvisor.com. All members of the public are hereby invited to provide their comments on the DLOF to SEBI with respect to the disclosures made in the DLOF. The public is requested to send a copy of the comments sent to SEBI, to the Company and to the Lead Manager to the Issue at their respective addresses mentioned herein. All comments must be received by the Company or by the Lead Manager on or before 5 p.m. on the 21st (twenty first) day from the aforementioned date of filing the DLOF with SEBI.

This announcement has been prepared for publication in India and may not be released in any other jurisdiction. Please note that the distribution of the DLOF and the Issue of equity shares on rights basis to persons in certain jurisdictions outside India may be restricted by legal requirements prevailing in those jurisdictions. Accordingly, any person who acquires Rights Entitlements or Rights Equity Shares will be deemed to have declared, warranted and agreed that at the time of subscribing for the Rights Equity Shares or the Rights Entitlements, such person is not and will not be in the United States and/or in other restricted jurisdictions. The Rights Equity Shares of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or in any other jurisdiction which have any restrictions in connection with offering, issuing and allotting Rights Equity Shares within its jurisdiction, and/or to its citizens. The offering to which the DLOF relates is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States or any other jurisdiction other than India or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlementment.

Investments in equity and equity related securities involve a high degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read "risk factors" carefully before taking an investment decision in relation to this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and the Issue including the risks involved. The securities being offered in the Issue have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the DLOF. Investors are advised to refer to the section titled "Risk Factors" beginning on page 16 of the DLOF before making an investment in this Issue.

Note: Capitalised terms not defined herein shall have the same meanings ascribed to such terms in the DLOF.

LEAD MANAGER TO THE ISSUE

SAFFRON

SAFFRON CAPITAL ADVISORS PRIVATE LIMITED
605, 6th floor, Centre Point, Andheri Kurla Road, J.B. Nagar, Andheri (East)
Mumbai - 400 059, Maharashtra, India.
Telephone: +91 22 4082 0914/915; **Facsimile:** +91 22 4082 0999
E-mail: rights.issue@saffronadvisor.com **Website:** www.saffronadvisor.com
Investor grievance email: investor@grievance@saffronadvisor.com
Contact Person: Mr. Amit Wagle/ Gaurav Khandelwal
SEBI Registration Number: INM 000011211

(This is a public announcement for information purposes only and not for publication or distribution and is not an Offer Document)
(Not for distribution outside India)



LASA SUPERGENERICS LIMITED

Our Company was incorporated as "Lasa Supergenerics Limited" on March 11, 2016 as a public company under the provisions of Companies Act, 2013 having registration number 274202 of 2016 with the Registrar of Companies, Mumbai ("RoC"). Our Company has received its Certificate of Incorporation dated March 11, 2016 from the Registrar of Companies, Mumbai.

Registered Office: C-105, MIDC, Mahad, Raigad - 402301, Maharashtra, India
Telephone: +91 21-4523-2101 / 202; Fax: NA
Contact Person: Nidhi Kulshreshtha, Company Secretary and Compliance Officer.
E-mail: cs@lasalabs.com; Website: www.lasalabs.com
Corporate Identity Number: L24233MH2016PLC274202

PROMOTER OF THE COMPANY: OMKAR HERLEKAR

ISSUE OF [n] EQUITY SHARES WITH A FACE VALUE OF ₹ 10 EACH ("RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ [n] PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [n] PER RIGHTS EQUITY SHARE AGGREGATING UPTO ₹ 6,000 LACS TO OUR ELIGIBLE EQUITY SHAREHOLDERS ON A RIGHTS BASIS IN THE RATIO OF [n] FULLY PAID-UP RIGHTS EQUITY SHARE(S) FOR EVERY [n] FULLY PAID-UP EQUITY SHARE(S) HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. [n] ("THE ISSUE"). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARE IS [n] TIMES THE FACE VALUE OF THE EQUITY SHARE. FOR FURTHER DETAILS, PLEASE SEE THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE [n] OF THE DLOF.

This public announcement is being made in compliance with the provisions of Regulation 9(3) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended (the "SEBI ICDR Regulations"), to state that Lasa Supergenerics Limited is proposing, subject to requisite approvals, market conditions and other considerations, an issue of equity shares to equity shareholders on a rights basis and has on November 6, 2018 filed the Draft Letter of Offer ("DLOF") with the Securities and Exchange Board of India (the "SEBI") at Mumbai, Maharashtra.

Pursuant to Regulation 9(1) of the SEBI ICDR Regulations, the DLOF filed with SEBI is open to public, for comments, if any. The DLOF is hosted on the website of SEBI at www.sebi.gov.in, website of recognized stock exchanges where the equity shares are listed i.e. BSE Limited at www.bseindia.com and the National Stock Exchange of India Limited at www.nseindia.com and website of the Lead Manager i.e. Saffron Capital Advisors Private Limited at www.saffronadvisor.com. All members of the public are hereby invited to provide their comments on the DLOF to SEBI with respect to the disclosures made in the DLOF. The public is requested to send a copy of the comments sent to SEBI, to the Company and to the Lead Manager to the Issue at their respective addresses mentioned herein. All comments must be received by the Company or by the Lead Manager on or before 5 p.m. on the 21st (twenty first) day from the aforementioned date of filing the DLOF with SEBI.

This announcement has been prepared for publication in India and may not be released in any other jurisdiction. Please note that the distribution of the DLOF and the Issue of equity shares on rights basis to persons in certain jurisdictions outside India may be restricted by legal requirements prevailing in those jurisdictions. Accordingly, any person who acquires Rights Entitlements or Rights Equity Shares will be deemed to have declared, warranted and agreed that at the time of subscribing for the Rights Equity Shares or the Rights Entitlements, such person is not and will not be in the United States and/or in other restricted jurisdictions. The Rights Equity Shares of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or in any other jurisdiction which have any restrictions in connection with offering, issuing and allotting Rights Equity Shares within its jurisdiction, and/or to its citizens. The offering to which the DLOF relates is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States or any other jurisdiction other than India or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlement.

Investments in equity and equity related securities involve a high degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read "risk factors" carefully before taking an investment decision in relation to this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and the Issue including the risks involved. The securities being offered in the Issue have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the DLOF. Investors are advised to refer to the section titled "Risk Factors" beginning on page 16 of the DLOF before making an investment in this Issue.

Note: Capitalised terms not defined herein shall have the same meanings ascribed to such terms in the DLOF.

LEAD MANAGER TO THE ISSUE



SAFFRON CAPITAL ADVISORS PRIVATE LIMITED
605, 6th floor, Centre Point, Andheri Kurla Road, J.B. Nagar, Andheri (East)
Mumbai - 400 059, Maharashtra, India.
Telephone: +91 22 4082 0914/915; Facsimile: +91 22 4082 0999
E-mail: rights.issue@saffronadvisor.com Website: www.saffronadvisor.com
Investor grievance email: investor@grievance@saffronadvisor.com
Contact Person: Mr. Amit Wagle/ Gaurav Khandelwal
SEBI Registration Number: INM 000011211

For LASA SUPERGENERICS LIMITED

Date: November 6, 2018
Place: Mumbai

Disclaimer: "Lasa Supergenerics Limited" is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the website of the Lead Manager at Saffron Capital Advisors Private Limited at www.saffronadvisor.com. Investors should note that investment in securities involves a high degree of risk and are requested to refer to the DLOF, including the section "Risk Factors" beginning on page 16 of the DLOF.

हम इसमें शामिल हैं।
क्या 5जी के लिए यह उचित वक्त है?
जहां तक 5जी की तैयारियों का सवाल है, मुझे ऐसा नहीं लगता कि तकनीक के हिसाब से भारत कहीं पीछे है। भारत विकसित देशों के साथ ही तैयार हो जाएगा। नई तकनीक के लिए बुनियादी ढांचा में भारी निवेश की जरूरत होगी, हमें फाइबर में निवेश करना होगा। इस समय सिर्फ 20 प्रतिशत के करीब मोबाइल टावर फाइबर के माध्यम से जुड़े हैं। हमें इनका प्रतिशत बढ़ाकर 80 तक ले जाना होगा। 5जी की सफलता के लिए फाइबर में निवेश प्राथमिक जरूरत है। जहां तक तकनीक का सवाल है, हम पीछे नहीं हैं।
अगर दूरसंचार विभाग कहता है तो क्या ट्राई स्पेक्ट्रम के मूल्य को लेकर अपनी सिफारिशों पर फिर से विचार करेंगे? मैं इस काल्पनिक सवाल का जवाब नहीं दे सकता। जब ऐसा होगा, तब विचार किया जाएगा। बहरहाल हमने आरक्षित मूल्य पर अपनी सिफारिश दूरसंचार विभाग को दे दी है।

रेटिंग 274

7	8
9	6
	6
1	2
	3
6	

परिणाम संख्या 3273

4	5	8	6	3	2	9	1	7
3	1	6	5	9	7	4	8	2
7	9	2	1	4	8	6	3	5
5	6	1	4	2	9	8	7	3
9	4	7	8	5	3	1	2	6
8	2	3	7	1	6	5	4	9
1	7	4	3	6	5	2	9	8
2	3	5	9	8	1	7	6	4
6	8	9	2	7	4	3	5	1

कैसे खेलें?
हर रोल, कॉलम और 3 बाई 3 के बॉक्स में एक से लेकर नौ तक की संख्या भरें।

मुश्किल



य प्रदेश

दी अतिरिक्त: किराना (किलो): 255/295, हल्दी: सांगली 119/ निजामाबाद 101/111, कालीमिर्च 50, जीरा: ऊंझा चालू 214/226, म 239/249, बेस्ट 249/259, स 325/480, बड़ी इलायची 650/ 50, दालचीनी 180/195, जायफल 100, जावित्री कोचीन 1575/1625, मुर 1575/1650, अजवायन 90/150, धनिया खड़ा मीडियम धोखाध 5, मेथीदाना 40/43, मेवे: काजू अधिकांश 780/860, (320 नं.) 840/850, हॉनाक नं.) 800/810, एसएडब्ल्यू कोलकाता नं.) 800/820, किशमिश: कंधारी 100, इंडियन 190/200, गोल्डन 20, मखाना 600/750, पिस्ता: बड़ा किया 250, पेशावरी 1700/1750, हैराती लिए ईनमकीन 875/925, मगज तरबूज

130/140, केसर (प्रति ग्राम) 180, सफेद मूसली 1600/1700, अखरोट 350/500, अमरीकन 450/500, गिरी 800/1200, अंजीर 350/600, जरदालू 450/700, बादयान 170/180, चारोली 600/700, मुनक्का 250/600, अनाज-दाल (क्विं): चावल परमल 2500/2900, बासमती 'मोगरा 3850/4025, गेहूं 1800/2200, चना कांठेवाला 4200/4300, काबली चना डॉलर 5000/5200, चना दाल 4700/4800, मसूर 3700/3900, मसूर दाल 4400/4500, मूंग 5000/5800, तुअर 4200/4500, उड़द 4200/5600, उड़द मोगर 5500/6000, मक्का 1200/1250, तिलहन: सोयाबीन 3200/3300, सरसों 3800/4500, कापस्या खली 1700/1800, खाद्य तेल (टीन): सरसों 1300/1350, सोयाबीन 1200/1225, मूंगफली 2100/2150, खोपरा 2400/2600, वनस्पति 1100/1175, सूरजमुखी 1325/1400, चीनी: एस-तीस 3500/3550 एनएनएस

